SCHEDULE: Morgan Stanley Discloses 5.8% Stake in Semler Scientific
Beneficial Ownership Report
Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have disclosed a 5.8% beneficial ownership stake in Semler Scientific, Inc.
Summary
- Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley Investment Management Inc., have filed a Schedule 13G reporting beneficial ownership of common stock in Semler Scientific, Inc.
- As of June 30, 2025, Morgan Stanley beneficially owned an aggregate of 790,603 shares of Semler Scientific common stock, representing 5.8% of the class.
- Morgan Stanley Investment Management Inc. beneficially owned 788,492 shares, also representing 5.8% of the class.
- The shares are stated to be acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Semler Scientific.
Sentiment
Score: 6
Explanation: The filing is a standard beneficial ownership disclosure. The presence of a significant stake by a major financial institution like Morgan Stanley can be viewed as a positive signal of institutional interest in Semler Scientific, Inc.
Positives
- Significant institutional investment from Morgan Stanley and its subsidiary, indicating potential confidence or strategic interest in Semler Scientific, Inc.
Future Outlook
NA
Industry Context
This filing indicates a major financial institution's significant stake in a company, which can be seen as a vote of confidence or a strategic investment within the healthcare technology or medical device sector, where Semler Scientific operates.
Related Party Transactions
- Morgan Stanley Investment Management Inc. is a wholly-owned subsidiary of Morgan Stanley, and their beneficial ownership is reported jointly, reflecting the parent-subsidiary relationship.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which may influence investor sentiment and perception of the company's stability and attractiveness.
- Company Management: Awareness of a major institutional shareholder may influence strategic decisions or engagement with the investor.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement. |
| 08/07/2025 | Signature date for Morgan Stanley and Morgan Stanley Investment Management Inc. |
Keywords
Semler Scientific, Morgan Stanley, Morgan Stanley Investment Management, beneficial ownership, common stock, institutional investment, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.